Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2014—MoFlo Astrios EQ, a six-way, jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent-pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter.
July 2014—The FilmArray BCID Panel M235 from Maine Molecular Quality Controls is for in vitro use as a quality control to monitor the detection and identification of 24 pathogens and three antibiotic-resistance genes associated with bloodstream infections when tested by the FilmArray Blood Culture Identification Panel. The kit contains 12 tubes, 100 µL each, of synthetic DNA suspended in a noninfectious solution of buffers, preservatives, and stabilizers and should be stored at 2°–8°C.
July 2014—Copan and MetaSystems signed a global and exclusive agreement for the integration of an automatic microscopy slide scanning system, provided by MetaSystems, with WASPLab. The partnership provides Copan customers a fully automated system for the acquisition of microscopy images of Gram slides (under the brand Metafer) integrated with the WASPLab environment.
July 2014—The Clinical and Laboratory Standards Institute released Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline—Second Edition (MM09-A2) and published a new document, Microarrays for Diagnosis and Monitoring of Infectious Diseases; Approved Guideline (MM22-A).
July 2014—Kaluza for Gallios software for the Beckman Coulter Gallios cytometer uses data acquisition tools to increase efficiency and performance in the cell characterization and analysis workflow of core research laboratories. The software features a guided, intuitive drag-and-drop interface and facilitates creation of the right setup for accurate plot output. Visual management tools enable tracking of instrument function and experiment progress. Voltage and compensation can be quickly changed, and unlimited “undo” aids new users.
July 2014—Designed specifically for point-of-care testing, Radiometer’s ABL90 Flex is a compact, acute care analyzer with optional wireless capability, making it possible to place it near the patient and close to the OR, ED, ICU, or a step-down unit.
June 2014—Chembio will begin marketing and selling the FDA-approved and CLIA-waived Chembio HIV 1/2 STAT-PAK assay in the U.S. market.
June 2014—Beckman Coulter entered into an agreement to acquire Xitogen Technologies together with Cytojene Corp. Xitogen, a flow cytometer developer based in Suzhou and Dalian, China, will provide Beckman Coulter Life Sciences with an operational base in the China market, and the facilities in Suzhou and Dalian will function as research and development and manufacturing centers.
June 2014—The Poly stat Flu A & B kit from Polymedco is an in vitro, rapid qualitative test that detects influenza type A and B, including numerous strains of H1N1, directly from a nasal or nasopharyngeal swab, as well as nasopharyngeal aspirate/wash specimens.
June 2014—Research presented at the annual conference of the American Society of Breast Surgeons in May reported that molecular subtyping using Agendia’s MammaPrint and BluePrint tests can provide guidance about whether to propose neoadjuvant treatment and what kind of treatment to recommend.
